CASI Pharmaceuticals (CASIF) Other Non-Current Liabilities (2021 - 2025)

CASI Pharmaceuticals has reported Other Non-Current Liabilities for 5 years, with the latest figure at $13.3 million in Q4 2025.

• For the quarter ending Q4 2025, Other Non-Current Liabilities fell 13.72% year-over-year to $13.3 million; the trailing twelve-month figure through Dec 2025 stood at $13.3 million (down 13.72% YoY), and the FY2025 full-year result was $13.3 million, down 13.72% from the prior year.
• Other Non-Current Liabilities for Q4 2025 stood at $13.3 million, down from $13.6 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $15.5 billion in Q4 2023, with the low at $12.3 million in Q4 2022.
• Historically, Other Non-Current Liabilities has averaged $5.2 billion across 5 years, with a median of $15.4 million in 2024.
• Annual changes were most pronounced in 2023 — Other Non-Current Liabilities surged 125800.63% — and 2025, when it slumped 99.9%.
• CASI Pharmaceuticals' Other Non-Current Liabilities stood at $14.3 million in 2021, then declined by 14.16% to $12.3 million in 2022, then surged by 125800.63% to $15.5 billion in 2023, then tumbled by 99.9% to $15.4 million in 2024, then slipped by 13.72% to $13.3 million in 2025.
• The last three Other Non-Current Liabilities figures came in at $13.3 million (Q4 2025), $13.6 million (Q3 2025), and $13.8 million (Q2 2025), per Business Quant data.